Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

Calyxt, Inc.. (5/22/18). "Press Release: Calyxt Announces Successful Closing of $60.9 Million Public Offering". Minneapolis, MN.

Region Region United States (USA)
Organisations Organisation Calyxt Inc. (Nasdaq Global Market: CLXT)
  Group Cellectis (Group)
  Organisation 2 Citigroup Global Markets Inc.
  Group Citigroup (Group)
Products Product TALEN® technology (Transcription Activator-Like Effector Nuclease)
  Product 2 investment banking
Index term Index term Cellectis–SEVERAL: investment, 201805 public offering of Calyxt Inc $60.9m 4.6m+457k shares common stockat $15/share
Persons Person Moore, Jennifer (Cellectis 201511 VP Communications)
  Person 2 Kasunich, Caitlin (KSCA Strategic Communications 201706)

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) and Calyxt, Inc. (NASDAQ: CLXT) today announced the closing of Calyxt’s follow-on public offering of 4,057,500 shares of Calyxt’s common stock (inclusive of the full exercise by the underwriters of their option to purchase 457,500 additional shares) at a public offering price of $15.00 per share. The gross proceeds to Calyxt from the offering are approximately $60.9 million, before deducting the estimated expenses related to the offering and the underwriting discounts and commissions payable by Calyxt. Calyxt’s common stock is listed on the Nasdaq Global Market under the symbol “CLXT”.

Calyxt is a consumer-centric food- and agriculture-focused company. As of closing, Cellectis owns approximately 70.6% of Calyxt’s outstanding shares of common stock.

Citigroup, Goldman Sachs & Co. LLC and Jefferies acted as book-running managers for the offering. Wells Fargo Securities acted as lead manager and BMO Capital Markets Corp. acted as co-manager.

A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission and was declared effective on May 17, 2018. This offering was made only by means of a prospectus. A copy of the prospectus may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by facsimile at (212) 902-9316, or by email at; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For further information, please contact:

For Calyxt

Media contacts

Jennifer Moore, VP Communications
Phone: 917-580-1088

Caitlin Kasunich / Nick Opich
KCSA Strategic Communications
212.896.1241 / 212.896.1206
email: /

Investor Relations contact

Simon Harnest, VP Corporate Strategy and Finance
Phone: 646-385-9008

Record changed: 2018-05-23


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Cellectis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top